EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Minimal residual disease – guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

Maria Kislova iD, Elena Dmitrieva iD, Elena Naumova iD, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva iD, Tatiana Obukhova, Bella Biderman iD, Andrey Sudarikov iD, Egor Volchkov iD und 4 weitere

British Journal of Haematology · 2026-10 · 209 (4) · 1664-1672

DOI: 10.1111/bjh.70761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 19.08.2026. Verfasst von Maria Kislova und 15 weiteren Autor:innen. Beteiligte Einrichtung: Botkin Hospital, Moscow, Russia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Bridged Bicyclo Compounds, Heterocyclic, Adenine, Sulfonamides. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Autonomous Non-Profit Organization "Moscow Center for Innovative Technologies in Healthcare".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complex karyotype (CK) is a strong predictor of early progression and poor survival in chronic lymphocytic leukaemia (CLL), including during targeted therapy. Minimal residual disease (MRD)–guided therapy may improve outcomes by enabling deeper remissions and limiting clonal evolution. We present the final results of a prospective MRD‐guided ibrutinib and venetoclax (IVen) compared with a retrospective cohort treated with ibrutinib monotherapy (Imono). Eligible patients had CLL with high CK (≥5 aberrations) or CK with deletion 17p. The IVen cohort received 3 months of ibrutinib followed by up to 24 months of IVen combination therapy or until three consecutive undetectable MRD (uMRD) bone marrow assessments. Patients with detectable MRD after 24 months continue ibrutinib alone. Baseline characteristics showed numerical differences between cohorts that did not reach statistical significance. A total of 106 patients were included (IVen n = 50; Imono n = 56). With a median follow‐up of 42.1 months, IVen significantly improved progression‐free survival (PFS) (33.9 months vs. NR; hazard ratio [HR] 0.23, p < 0.001) and overall survival (OS) (47 months vs. NR; HR 0.48, p = 0.0186) compared with Imono, although comparisons are limited by the retrospective control design. uMRD was achieved in 66% of patients with IVen. These results support MRD‐adapted IVen as an optimal strategy for high‐risk CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellBridged Bicyclo Compounds, HeterocyclicAdenineSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasm, ResidualPiperidinesFemaleAgedMaleMiddle AgedAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

chronic lymphocytic leukaemiacomplex karyotypeibrutinibminimal residual diseasevenetoclax

Substanzen

Bridged Bicyclo Compounds, HeterocyclicAdeninePiperidinesvenetoclaxSulfonamidesibrutinib

Autor:innen und Institutionen

  • Botkin Hospital, Moscow, Russia.
  • Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
  • National Medical Research Center for Hematology, Moscow, Russia.
  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Laboratory of Single Cell Biology, Research Institute of Molecular and Cellular Medicine, Patrice Lumumba Peoples' Friendship University of Russia, Moscow, Russia.
  • R.M. Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russia.

ORCID-Profile: Maria Kislova, Elena Dmitrieva, Elena Naumova, Maria Gladysheva, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin

Förderung

  • Autonomous Non-Profit Organization "Moscow Center for Innovative Technologies in Healthcare"

Zitieren

APA

Kislova, M., Dmitrieva, E., Naumova, E., Pochtar, M., Lugovskaya, S., Kobzev, Y., Loban, A., Gladysheva, M., Obukhova, T., Biderman, B., Sudarikov, A., Volchkov, E., Ivanova, M., Ptushkin, V., Visentin, A., & Nikitin, E. (2026). Minimal residual disease – guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype. British Journal of Haematology, 209(4), 1664-1672. https://doi.org/10.1111/bjh.70761

Vancouver

Kislova M, Dmitrieva E, Naumova E, Pochtar M, Lugovskaya S, Kobzev Y, et al. Minimal residual disease – guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype. British Journal of Haematology. 2026;209(4):1664-1672. doi:10.1111/bjh.70761

BibTeX
@article{Kislova2026,
  author = {Kislova, Maria and Dmitrieva, Elena and Naumova, Elena and Pochtar, Margarita and Lugovskaya, Svetlana and Kobzev, Yury and Loban, Alla and Gladysheva, Maria and Obukhova, Tatiana and Biderman, Bella and Sudarikov, Andrey and Volchkov, Egor and Ivanova, Maria and Ptushkin, Vadim and Visentin, Andrea and Nikitin, Eugene},
  title = {Minimal residual disease – guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {4},
  pages = {1664--1672},
  doi = {10.1111/bjh.70761}
}
Kostenlos starten →